Table 1 Baseline characteristics of the study cohort

Females, n (%)

30 (54.5)

13 (52.0)

17 (56.7)

0.739^a

Age (years)

 Mean ± SD

 Min–max

53.8 ± 12.1

23–77

55.9 ± 13.4

23–77

52 ± 10.8

35–75

0.236^b

Disease duration (years)

 Mean ± SD

 Min–max

5.1 ± 6.1

1–30

5 ± 3.8

1–15

5.3 ± 7.6

1–30

0.326^a

Venom involved, n (%)

 Honeybee

 Wasp

 Honeybee and wasp

7 (12.7)

45 (81.8)

3 (5.5)

2 (8.0)

21 (84.0)

2 (8.0)

5 (16.7)

24 (80.0)

1 (3.3)

0.503^c

Severity of reaction, n (%)

 Mueller grade I

 Mueller grade II

 Mueller grade III

 Mueller grade IV

6 (10.9)

25 (45.5)

20 (36.4)

4 (7.3)

2 (8.0)

11 (44.0)

9 (36.0)

3 (12.0)

4 (13.3)

14 (46.7)

11 (36.7)

1 (3.3)

0.618^c

Venom immune therapy status, n (%)

 Currently ongoing

 Completed

 Intended

 Not intended

45 (81.8)

2 (3.6)

3 (5.5)

5 (9.1)

18 (72.0)

1 (4.0)

3 (12.0)

3 (12.0)

27 (90.0)

1 (3.3)

0 (0)

2 (6.7)

0.205^c

Venom immune therapy duration (months)

 Mean ± SD

 Min–max

27.6 ± 26.1

1–120

33.6 ± 33.6

1–120

23.5 ± 19.4

1–60

0.569^a